Inhibitors of formation of advanced glycation endproducts (AGEs)

A method of slowing deleterious effects of aging in an organism wherein said effects are formation of glycation endproducts or protein crosslinking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

• LR103:
• 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid,
• LR104:
• 4-(4-fluoro-3-chlorophenylurido)phenoxyisobutyrylamidophenyl-2-carboxylic acid,
• LR105:
• 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid,
• LR106:
• 4-(4-chlorobenzylaminophenoxyisobutyric)acid,
• LR107:
• 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid),
• LR108:
• 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109:
• 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid,
• LR110:
• 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid,
• LR111:
• 8-quinolinoxy acetic acid,
• LR112:
• 4,4′-bis[(methyleneoxyethyleneamino)phenoxy]isobutyric acid,
• LR113:
• L-8-quinolinolyl(acetylhistidine),
• LR114:
• 4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and
• LR115:
• L, α-4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]phenylalanine.

A method of slowing progress in a patient of complications resulting from diabetes wherein said complications result from formation of glycation endproducts or protein crosslinking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said patient wherein said compound is selected from the group consisting of:

• LR103:
• 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid,
• LR104:
• 4-(4-fluoro-3-chlorophenylurido)phenoxyisobutyrylamidophenyl-2-carboxylic acid,
• LR105:
• 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid,
• LR106:
• 4-(4-chlorobenzylaminophenoxyisobutyric)acid,
• LR107:
• 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid),
• LR108:
• 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109:
• 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid,
• LR110:
• 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid,
• LR111:
• 8-quinolinoxy acetic acid,
• LR112:
• 4,4′-bis[(methyleneoxyethyleneamino)phenoxy]isobutyric acid,
• LR113:
• L-8-quinolinolyl(acetylhistidine),
• LR114:
• 4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and
• LR115:
• L, α-4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]phenylalanine.

A method of slowing progress in a patient of rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, or atherosclerosis, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said patient wherein said compound is selected from the group consisting of:

• LR103:
• 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid,
• LR104:
• 4-(4-fluoro-3-chlorophenylurido)phenoxyisobutyrylamidophenyl-2-carboxylic acid,
• LR105:
• 1 [(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid,
• LR106:
• 4-(4-chlorobenzylaminophenoxyisobutyric)acid,
• LR107:
• 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid),
• LR108:
• 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid,
• LR109:
• 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid,
• LR110:
• 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid,
• LR111:
• 8-quinolinoxy acetic acid,
• LR112:
• 4,4′-bis [(methyleneoxyethyleneamino)phenoxy]isobutyric acid,
• LR113:
• L-8-quinolinolyl(acetylhistidine),
• LR114:
• 4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and
• LR115:
• L, α-4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]phenylalanine.

A method of preventing browning or Maillard reaction in foodstuffs wherein said method comprises mixing an effective amount of a compound or a pharmaceutically acceptable salt of said compound with said foodstuffs, wherein said effective amount inhibits formation of glycation endproducts or protein crosslinking, wherein said compound is selected from the group consisting of:

• LR103:
• 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]4-phenoxyisobutyric acid,
• LR104:
• 4-(4-fluoro-3-chlorophenylurido)phenoxyisobutyrylamidophenyl]-2-carboxylic acid,
• LR105:
• 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid,
• LR106:
• 4-(4-chlorobenzylaminophenoxyisobutyric)acid,
• LR107:
• 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid),
• LR108:
• 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]4-phenoxyisobutyric acid,
• LR109:
• 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid,
• LR110:
• 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric)acid,
• LR111:
• 8-quinolinoxy acetic acid,
• LR112:
• 4,4′-bis[(methyleneoxyethyleneamino)phenoxyl]isobutyric acid,
• LR113:
• L-8-quinolinolyl(acetylhistidine),
• LR114:
• 4[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and
• LR115:
• L, α-4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]phenylalanine.

A compound or a pharmaceutically acceptable salt of said compound wherein said compound is selected from the group consisting of:

• LR103:
• 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid,
• LR104:
• 4-(4-fluoro-3-chlorophenylurido)phenoxyisobutyrylamidophenyl-2-carboxylic acid,
• LR105:
• 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid,
• LR106:
• 4-(4-chlorobenzylaminophenoxyisobutyric)acid,
• LR107:
• 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid),
• LR108:
• 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid,
• LR109:
• 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid,
• LR110:
• 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric) acid,
• LR111:
• 8-quinolinoxy acetic acid,
• LR112:
• 4,4′-bis[(methyleneoxyethyleneamino)phenoxy]isobutyric acid,
• LR113:
• L-8-quinolinolyl(acetylhistidine),
• LR114:
• 4-[(3,5=dichlorophenyureido)phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and
• LR115:
• L, α-4-[(3,5-dichlorophenyureido) phenoxyisobutyrylamido]phenylalanine.